| Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation (NCT04902807) | Institut National de la Santé Et de la Recherche Médicale, France | 2021-09-07 |
| Metabolic Profiling of Immune Responses in Immune-mediated Diseases (NCT04864886) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-08-10 |
| COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency (NCT04724642) | Tel-Aviv Sourasky Medical Center | 2020-12-28 |
| A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency (NCT04566692) | Grifols Therapeutics LLC | 2020-11-24 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency (NCT04561115) | Grifols Therapeutics LLC | 2020-09-02 |
| Systematic Screening for Primary Immunodeficiencies in Patients Hospitalized for Severe Infections in Intensive Care. (NCT04356053) | University Hospital, Montpellier | 2020-04-01 |
| Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency (NCT03814798) | Grifols Therapeutics LLC | 2019-12-01 |
| Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies (NCT03610802) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-07-22 |
| Severe Immune Cytopenia Registry Www.Sic-reg.Org (NCT03576742) | Medical University of Graz | 2018-03-09 |
| Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant (NCT03330795) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-12-01 |
| NIAID Centralized Sequencing Protocol (NCT03206099) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-07-31 |
| Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) (NCT03033745) | CSL Behring | 2017-02-01 |
| What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)? (NCT03815357) | Murdoch Childrens Research Institute | 2017-01-31 |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study (NCT03733249) | Bellicum Pharmaceuticals | 2017-01-01 |
| IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia (NCT02881437) | University Hospital, Lille | 2016-11-11 |
| Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency (NCT02806986) | Grifols Therapeutics LLC | 2016-06-01 |
| CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL (NCT03907241) | Octapharma | 2016-03-01 |
| Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% (NCT02269163) | Prometic Biotherapeutics, Inc. | 2016-01-26 |
| ASIS for GAMMAGARD in Primary Immunodeficiency (NCT02123615) | ASIS Corporation | 2016-01-01 |
| Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency (NCT02604810) | Grifols Therapeutics LLC | 2016-01-01 |
| A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push (NCT02503293) | Octapharma | 2015-07-29 |
| Diagnostic Immunization With Rabies Vaccine in Patients With PID (NCT02490956) | Chulalongkorn University | 2015-04-01 |
| Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) (NCT01581593) | Kedrion S.p.A. | 2012-11-12 |
| Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency (NCT01465958) | Grifols Therapeutics LLC | 2011-11-01 |
| Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders (NCT00895271) | National Institute of Allergy and Infectious Diseases (NIAID) | 2009-06-10 |
| Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. (NCT00278954) | Bio Products Laboratory | 2006-01-01 |